Bioxytran Phase 2 trial of ProLectin-M shows 100% viral clearance at day 7 in COVID-19 patients

BIOXYTRAN, INC

100% of treated patients achieved viral clearance by day 7 vs 6% placebo (p=.001); 88% by day 3 vs 0% placebo.
No drug-related serious adverse events or viral rebounds during 14-day observation period.
NMR data show ProLectin-M binds galectin-3 with micromolar affinity (2 μM) and blocks S1 subunit and ACE2 receptors.
Results provide rationale for upcoming Phase 2/3 registrational trial.
Company plans to explore the galectin antagonist platform for other viruses and indications.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.